KYNAM CAPITAL MANAGEMENT LP
Q4 2024 Form 13-F

PRINCETON, NEW JERSEY
CIK 0001907884 · CRD 314368 · SEC-registered investment adviser
$1.7B Reported Value Total

KYNAM CAPITAL MANAGEMENT, LP reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $2,561,166,094, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-04-10
Reported value
$1.7B
Quarter over quarter
-5.4%
Holdings
29
Top-10 concentration
76.1%

Key People

Form ADV owners & control persons
Yue "nmn" Tang
LIMITED PARTNER
Jared Joseph Keller
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2024 13F record

Q4 2024 13F filing summary

Q4 2024 Form 13F portfolio summary
Period of report December 31, 2024
Filed February 14, 2025
Form 13F-HR
Reported value $1.7B
Positions 29
Change in reported value +29.7%
New positions 5
Exited positions 0
Position turnover 17.2%
Top-10 concentration 76.1%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
34 $1.8B
Q2 2026 13F
Filed Aug 14, 2026
32 $1.8B
Q1 2026 13F
Filed May 15, 2026
36 $1.6B
Q4 2025 13F
Filed Feb 17, 2026
35 $1.6B
Q3 2025 13F
Filed Nov 14, 2025
35 $1.3B
Q2 2025 13F
Filed Aug 14, 2025
31 $928.8M
Q1 2025 13F
Filed May 15, 2025
31 $1.2B
Q4 2024 13F
Filed Feb 14, 2025
29 $1.7B
Q3 2024 13F
Filed Nov 14, 2024
24 $1.3B
Q2 2024 13F
Filed Aug 14, 2024
22 $1.3B
Q1 2024 13F
Filed May 15, 2024
21 $955.5M
Q4 2023 13F
Filed Feb 14, 2024
23 $902.6M
Q3 2023 13F
Filed Nov 14, 2023
27 $611.4M
Q2 2023 13F
Filed Aug 14, 2023
23 $727.1M
Q1 2023 13F
Filed May 15, 2023
34 $774.6M
Q4 2022 13F
Filed Feb 14, 2023
31 $651.9M
Q3 2022 13F
Filed Nov 14, 2022
33 $474.6M
Q2 2022 13F
Filed Aug 15, 2022
31 $391.6M
Q1 2022 13F
Filed May 13, 2022
31 $308.3M
Q4 2021 13F
Filed Feb 14, 2022
30 $187.1M

Top 20 holdings · Q4 2024

Largest Q4 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 NTRA NATERA INC $320.1M 18.92%
2 PCVX VAXCYTE INC $191.3M 11.31%
3 SPY P SPDR S&P 500 ETF TR $175.8M 10.39%
4 CLDX CELLDEX THERAPEUTICS INC NEW $128.0M 7.56%
5 SNDX SYNDAX PHARMACEUTICALS INC $112.6M 6.66%
6 DVAX DYNAVAX TECHNOLOGIES CORP $83.8M 4.95%
7 CGON CG ONCOLOGY INC $72.3M 4.27%
8 COGT COGENT BIOSCIENCES INC $71.0M 4.2%
9 BCRX BIOCRYST PHARMACEUTICALS INC $68.3M 4.04%
10 VRDN VIRIDIAN THERAPEUTICS INC $63.8M 3.77%
11 VERA VERA THERAPEUTICS INC $61.7M 3.64%
12 WVE WAVE LIFE SCIENCES LTD $60.6M 3.58%
13 BEAM BEAM THERAPEUTICS INC $43.6M 2.57%
14 IMCR IMMUNOCORE HLDGS PLC $36.2M 2.14%
15 ENGN ENGENE HOLDINGS INC $33.2M 1.96%
16 TVTX TRAVERE THERAPEUTICS INC $31.4M 1.86%
17 LQDA LIQUIDIA CORPORATION $26.7M 1.58%
18 IRWD IRONWOOD PHARMACEUTICALS INC $20.8M 1.23%
19 TSVT 2SEVENTY BIO INC $17.5M 1.03%
20 CGEM CULLINAN THERAPEUTICS INC $15.3M 0.9%

Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings